Axxam announces the launch of Muna Therapeutics ApS with EUR 60 Million to advance novel small molecule therapeutics for neurodegenerative diseases

July 9, 2021

Milan (Italy) – Axxam is proud to announce that Muna Therapeutics, a biotech company founded in 2020 by Aarhus University, financed by Novo Seeds and receiving assets in exchange of equity from Axxam, was successful closing a EUR 60 million (US$ 73 million) Series A financing round today.

The investor syndicate was co-led by Novo Holdings, Sofinnova Partners, LSP Dementia Fund, and Droia Ventures, with Polaris Partners, Polaris Innovation Fund, Sanofi Ventures and V-Bio Ventures joining the round.

Axxam has the strategy of taking equity in promising drug discovery companies, by assigning valuable research assets either to already formed companies, such as Acousia Therapeutics GmbH or Muna Therapeutics ApS, as well as to start-ups, such as Rewind Therapeutics NV or Libra Therapeutics, Inc. Since 2016, these four drug discovery companies have collected more than EUR 110 million to advance the drug discovery programs transferred from Axxam into later stage development products.

For more information, please open the Press Release from Muna Therapeutics or visit Muna Therapeutics website

Contact us for more information






Scroll to Top